These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 11722420

  • 1. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children.
    Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehée A, Rohrlich P, Peuchmaur M, Matthieu-Boué A, Fischer A, Vilmer E.
    Br J Haematol; 2001 Oct; 115(1):112-8. PubMed ID: 11722420
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
    Luo XY, Mo XD, Xu LP, Zhang XH, Wang Y, Liu KY, Chang YJ, Zhao XY, Huang XJ.
    Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Lymphocyte data in Epstein-Barr-virus induced post-transplant lymphoproliferative disorder treated by rituximab.
    Entz-Werle N, Cojean N, Barats A, Eyer D, Munzer M, Uring-Lambert B, Falkenrodt A, Babin A, Lutz P.
    Pediatr Transplant; 2003 Aug; 7(4):277-81. PubMed ID: 12890005
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
    Yamamoto N, Nishimura N, Takeuchi M, Ito T, Yokozaki H, Hirase S, Kubokawa I, Mori T, Yanai T, Hayakawa A, Takeshima Y, Nishio H, Matsuo M, Imadome K, Iijima K.
    Eur J Pediatr; 2014 Dec; 173(12):1615-8. PubMed ID: 24169729
    [Abstract] [Full Text] [Related]

  • 14. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
    Berney T, Delis S, Kato T, Nishida S, Mittal NK, Madariaga J, Levi D, Nery JR, Cirocco RE, Gelman B, Ruiz P, Tzakis AG.
    Transplantation; 2002 Oct 15; 74(7):1000-6. PubMed ID: 12394845
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
    Garceau P, Couture C, Cantin B, Bernier V, Sénéchal M.
    J Heart Lung Transplant; 2008 Aug 15; 27(8):928-31. PubMed ID: 18656811
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.
    Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, Marks DI, Jackson B, Chakupurakal G, Dennis M, Lim Z, Cook G, Carpenter B, Pettitt AR, Mathew S, Connelly-Smith L, Yin JA, Viskaduraki M, Chakraverty R, Orchard K, Shaw BE, Byrne JL, Brookes C, Craddock CF, Chaganti S.
    Bone Marrow Transplant; 2014 Feb 15; 49(2):280-6. PubMed ID: 24212561
    [Abstract] [Full Text] [Related]

  • 20. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S, German PTLD Study Group, European PTLD Network.
    Lancet Oncol; 2012 Feb 15; 13(2):196-206. PubMed ID: 22173060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.